Intellia Therapeutics Faces Continued Legal Battle Over Patent Infringement in $100M Deal with Regeneron

In a significant legal development, Intellia Therapeutics is facing ongoing patent infringement claims from BlueAllele. The biotechnology company, known for its gene-editing technologies, is accused of infringing on three patents held by BlueAllele, which were allegedly violated to secure a lucrative over $100 million agreement with Regeneron Pharmaceuticals. A federal judge in Pennsylvania has ruled that BlueAllele’s allegations are sufficiently plausible, specifically arguing that Intellia is not shielded by the drug-development safe harbor. This ruling implies that Intellia will need to continue to contest these claims in court. For further details, refer to the full report.